File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus

TitleUmbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus
Authors
Issue Date2010
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/
Citation
Arthritis And Rheumatism, 2010, v. 62 n. 8, p. 2467-2475 How to Cite?
AbstractObjective. Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have shown marked therapeutic effects in a number of diseases in animal studies, based on their potential for self-renewal and differentiation. No data are available on the effectiveness of UC MSC transplantation (MSCT) in human autoimmune disease. This study was undertaken to assess the efficacy and safety of allogeneic UC MSCT in patients with severe and treatment-refractory systemic lupus erythematosus (SLE). Methods. We conducted a single-arm trial that involved 16 SLE patients whose disease was refractory to standard treatment or who had life-threatening visceral involvement. All of the patients gave consent and underwent UC MSCT. Clinical changes were evaluated before and after transplantation using the SLE Disease Activity Index (SLEDAI), measurement of serum antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA) antibody, serum complement C3 and C4, and albumin levels, and assessment of and renal function. Evaluation of potential mechanisms of MSCT effects focused on the percentage of peripheral blood Treg cells and serum levels of cytokines. Results. From April 2007 to July 2009, a total of 16 patients with active SLE were enrolled and underwent UC MSCT. The median followup time after MSCT was 8.25 months (range 3-28 months). Significant improvements in the SLEDAI score, levels of serum ANA, anti-dsDNA antibody, serum albumin, and complement C3, and renal function were observed. Clinical remission was accompanied by an increase in peripheral Treg cells and a re-established balance between Th1- and Th2-related cytokines. Significant reduction in disease activity was achieved in all patients, and there has been no recurrence to date and no treatment-related deaths. Conclusion. Our findings indicate that UC MSCT results in amelioration of disease activity, serologic changes, and stabilization of proinflammatory cytokines. These data provide a foundation for conducting a randomized controlled trial of this new therapy for severe and treatment-refractory SLE. © 2010, American College of Rheumatology.
Persistent Identifierhttp://hdl.handle.net/10722/129501
ISSN
2015 Impact Factor: 8.955
2015 SCImago Journal Rankings: 3.206
ISI Accession Number ID
Funding AgencyGrant Number
National Natural Science Foundation of China30972736
30772014
Jiangsu Province Science and Technology Achievement Transformation FoundationBA2009124
Chinese National 115 Supporting Program2008BAI59B02
Jiangsu Province Natural Science FoundationBK2009034
Jiangsu Province 135 Talent FoundationRC2007002
Jiangsu Province Six Summit Talent Foundation
Nanjing Public Health Bureau Key Medical ProjectZKX09025
Funding Information:

Dr. Sun's work was supported by the National Natural Science Foundation of China (grants 30972736 and 30772014), the Jiangsu Province Science and Technology Achievement Transformation Foundation (grant BA2009124), the Chinese National 115 Supporting Program (grant 2008BAI59B02), the Jiangsu Province Natural Science Foundation (grant BK2009034), the Jiangsu Province 135 Talent Foundation (grant RC2007002), the Jiangsu Province Six Summit Talent Foundation, and the Nanjing Public Health Bureau Key Medical Project (grant ZKX09025).

References

 

DC FieldValueLanguage
dc.contributor.authorSun, Len_HK
dc.contributor.authorWang, Den_HK
dc.contributor.authorLiang, Jen_HK
dc.contributor.authorZhang, Hen_HK
dc.contributor.authorFeng, Xen_HK
dc.contributor.authorWang, Hen_HK
dc.contributor.authorHua, Ben_HK
dc.contributor.authorLiu, Ben_HK
dc.contributor.authorYe, Sen_HK
dc.contributor.authorHu, Xen_HK
dc.contributor.authorXu, Wen_HK
dc.contributor.authorZeng, Xen_HK
dc.contributor.authorHou, Yen_HK
dc.contributor.authorGilkeson, GSen_HK
dc.contributor.authorSilver, RMen_HK
dc.contributor.authorLu, Len_HK
dc.contributor.authorShi, Sen_HK
dc.date.accessioned2010-12-23T08:38:11Z-
dc.date.available2010-12-23T08:38:11Z-
dc.date.issued2010en_HK
dc.identifier.citationArthritis And Rheumatism, 2010, v. 62 n. 8, p. 2467-2475en_HK
dc.identifier.issn0004-3591en_HK
dc.identifier.urihttp://hdl.handle.net/10722/129501-
dc.description.abstractObjective. Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have shown marked therapeutic effects in a number of diseases in animal studies, based on their potential for self-renewal and differentiation. No data are available on the effectiveness of UC MSC transplantation (MSCT) in human autoimmune disease. This study was undertaken to assess the efficacy and safety of allogeneic UC MSCT in patients with severe and treatment-refractory systemic lupus erythematosus (SLE). Methods. We conducted a single-arm trial that involved 16 SLE patients whose disease was refractory to standard treatment or who had life-threatening visceral involvement. All of the patients gave consent and underwent UC MSCT. Clinical changes were evaluated before and after transplantation using the SLE Disease Activity Index (SLEDAI), measurement of serum antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA) antibody, serum complement C3 and C4, and albumin levels, and assessment of and renal function. Evaluation of potential mechanisms of MSCT effects focused on the percentage of peripheral blood Treg cells and serum levels of cytokines. Results. From April 2007 to July 2009, a total of 16 patients with active SLE were enrolled and underwent UC MSCT. The median followup time after MSCT was 8.25 months (range 3-28 months). Significant improvements in the SLEDAI score, levels of serum ANA, anti-dsDNA antibody, serum albumin, and complement C3, and renal function were observed. Clinical remission was accompanied by an increase in peripheral Treg cells and a re-established balance between Th1- and Th2-related cytokines. Significant reduction in disease activity was achieved in all patients, and there has been no recurrence to date and no treatment-related deaths. Conclusion. Our findings indicate that UC MSCT results in amelioration of disease activity, serologic changes, and stabilization of proinflammatory cytokines. These data provide a foundation for conducting a randomized controlled trial of this new therapy for severe and treatment-refractory SLE. © 2010, American College of Rheumatology.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/en_HK
dc.relation.ispartofArthritis and Rheumatismen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntibodies, Antinuclear - blood - immunologyen_HK
dc.subject.meshComplement C3 - immunology - metabolismen_HK
dc.subject.meshComplement C4 - immunology - metabolismen_HK
dc.subject.meshDNA - blood - immunologyen_HK
dc.subject.meshDisease Progressionen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLupus Erythematosus, Systemic - blood - immunology - therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMesenchymal Stem Cell Transplantationen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.subject.meshTransplantation, Homologousen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleUmbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1529-0131 (Electronic)0004-3591 (Linkin&volume=62&issue=8&spage=2467&epage=75&date=2010&atitle=Umbilical+cord+mesenchymal+stem+cell+transplantation+in+severe+and+refractory+systemic+lupus+erythematosusen_US
dc.identifier.emailLu, L:liweilu@hkucc.hku.hken_HK
dc.identifier.authorityLu, L=rp00477en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/art.27548en_HK
dc.identifier.pmid20506343-
dc.identifier.scopuseid_2-s2.0-77955361735en_HK
dc.identifier.hkuros176947en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77955361735&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume62en_HK
dc.identifier.issue8en_HK
dc.identifier.spage2467en_HK
dc.identifier.epage2475en_HK
dc.identifier.eissn1529-0131-
dc.identifier.isiWOS:000282762100032-
dc.publisher.placeUnited Statesen_HK
dc.identifier.citeulike7929905-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats